CDC and the Michigan Department of Community Health (MDCH) continue to investigate West Nile Virus (WNV) infection in a woman, who received a blood product later found with evidence of WNV, and in her child, who was exposed to breast milk later found to be WNV positive by TaqMan ® (1) . This report updates the findings of this investigation.
On September 2, 2002, a woman aged 40 years delivered a healthy infant but required transfusion of two units of packed red blood cells (RBC) for anemia. The patient received the first unit 6 hours after delivery and the second on the following day. The second transfusion was derived from the same donation as a unit of platelets given to a liver transplant recipient who developed confirmed West Nile meningoencephalitis (WNME); the blood donor's original tubing segment from this common donation was WNV positive by TaqMan ® (1) . Approximately 2 hours after delivery, the patient developed a migraine headache, photophobia, and anomia. The patient had a history of migraine headaches. When she was discharged 2 days after delivery, her headache was resolving. Eight days later, the patient developed a severe, persistent headache that differed qualitatively from her migraine headache. Twelve days after delivery, the patient reported developing fever, and 3 days later she was admitted with a fever of 102.8º F (39.3º C) and peripheral white blood count (WBC) of 2,900/mm 3 (normal: 3,900-11,100/mm 3 ). Laboratory examination of the cerebrospinal fluid (CSF) revealed a WBC count of 134/mm 3 (normal: <10/mm 3 ) with 10% neutrophils, a protein concentration of 57 mg/dL (normal: 12-60 mg/dL), and a glucose concentration of 57 mg/dL (normal: 40-70 mg/dL). Computerized tomography of the head was normal. A CSF sample tested at MDCH was positive for WNV-specific IgM. The woman recovered from WNME and was discharged from the hospital.
On the day of delivery, the mother began breast-feeding her child and continued (i.e., 6 days after symptom onset) through the second day of the hospitalization for WNME. An undiluted sample of breast milk obtained 16 days after delivery tested positive for WNV by TaqMan ® and for WNVspecific IgM and IgG antibody at CDC. Virus culture of this specimen is pending. Testing of a second sample of breast milk collected 24 days after the implicated transfusion was WNV RNA-negative by TaqMan ® at MDCH and CDC. A 1:400 dilution of this sample was again WNV-specific IgMpositive at CDC. Although the infant has remained afebrile and healthy, a serum sample from the infant at age 25 days was WNV-specific IgM-positive in testing performed at MDCH and CDC. No cord blood or other products of conception were available for testing. The mother reported that the infant has had little outdoor or other exposure to mosquitoes.
Editorial Note: This report describes two patients who tested positive for WNV infection after receipt of blood products from a single donation. The retention segment from the donation was positive for WNV by TaqMan ® . Although it is possible that both persons became infected from mosquito bites, these findings indicate that the patients became infected through transfusion of blood products. An ongoing investigation in Mississippi isolated WNV in FFP. The retention segment from the donation from which this FFP was made was positive for WNV by TaqMan ® , and the donor developed WNV-specific IgM antibody after donation. The ongoing investigation provides additional evidence that WNV can be transmitted through blood transfusion (1) . Additional case investigations conducted by CDC, FDA, and health departments will help to define the risk for WNV transmission through blood transfusion and organ transplantation. Because of the risk for WNV transmission through blood transfusion, efforts to develop a blood screening test are under way.
WNV RNA has not been identified previously in breast milk, and no studies are known that define the implications of this laboratory finding. Laboratory investigations, including attempts to culture WNV from additional breast milk samples, are under way. Until live virus is cultured from breast milk, or until definitive data are obtained to document WNV transmission through breast milk, the TaqMan ® findings described in this report should be interpreted with caution.
The risk for transmission of WNV from mother to infant through breast-feeding is unknown. The infant described in this report remains healthy despite breast-feeding for 17 days. Until follow-up testing on the infant is completed, it is unknown whether the infant was infected with WNV. The health benefits of breast-feeding are well established (2) , and these findings do not suggest a change in breast-feeding recommendations.
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Update: Influenza ActivityUnited States and Worldwide, June-September, 2002
During June-September 2002, influenza A (H3N2) and B viruses circulated worldwide and were associated with mild to moderate levels of disease activity. Influenza B viruses predominated in Africa, and both influenza A (H3N2) and B viruses circulated widely in Asia, Oceania, and Latin America, except in Chile and Taiwan, where A (H1)* viruses predominated. In North America, sporadic isolates of influenza A (H3N2), A (H1), and B viruses were identified. This report summarizes influenza activity in the United States and worldwide during June-September 2002 † . Influenza activity in North America typically peaks during December-March, which underscores the need to begin vaccinating against influenza in October and to continue vaccination into December and throughout the influenza season (1).
United States
Influenza surveillance is conducted by a network comprising four components, including approximately 700 sentinel providers and approximately 120 U.S. World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories (2) . During previous influenza seasons, active surveillance was conducted only from October to mid-May. In 2002, approximately 120 sentinel providers and approximately 60 U.S. WHO and NREVSS collaborating laboratories continued to submit weekly reports after mid-May. During May 19-September 21, the weekly percentage of patient visits to sentinel providers for influenza-like illness ranged from 1.0% in mid-May to 0.5% in mid-September. During this period, WHO and NREVSS collaborating laboratories tested 10,370 respiratory specimens for influenza viruses, of which 145 (1.4%) were positive. Of the positive results, 138 (95.2%) were influenza B viruses and seven (4.8%) were influenza A viruses. Influenza viruses were reported each week from midMay through mid-July and during the weeks ending July 27 and August 31. No influenza viruses have been reported for September.
From mid-May through early June, outbreaks of influenza B viruses were reported in schools in Hawaii, Oregon, and Texas. In mid-August, a cluster of five influenza A (H3N2) cases associated with a cruise and land tour in Alaska and the Yukon was reported by Health Canada. Ongoing surveillance conducted by the tour company detected no increase in respiratory illness (3).
Worldwide
During June-September, influenza A (H3N2) and B viruses circulated widely in Asia and Oceania; influenza A (H1) viruses were identified infrequently and were not associated with widespread activity, except in Taiwan, where they predominated. In Africa, influenza B viruses predominated. However, Madagascar reported an outbreak of influenza A (H3N2) viruses associated with elevated morbidity and mortality (4). In Latin America, influenza A (H3N2) and B viruses circulated widely and were associated with outbreaks. Influenza A (H1) viruses were identified less frequently, except in Chile, where they predominated. Influenza B viruses predominated in Argentina and were associated with an outbreak in August among school-aged children and their contacts. Influenza A (H3N2) and B viruses circulated widely in Brazil and Peru. In Canada, an outbreak in a long-termcare facility in August was associated with influenza A (H3N2) viruses; influenza A (H3N2), A (H1), and B viruses were identified sporadically throughout the summer. Although the number of influenza viruses reported to CDC this summer is greater than the number reported in the previous 12 summers, this increase probably reflects the institution of systematic reporting rather than a true increase in summer influenza activity.
Characterization of Influenza Virus Isolates
Although the influenza virus type/subtype that will predominate and the onset, peak, and severity of influenza-related disease activity for the 2002-03 influenza season cannot be predicted, the optimal time to receive influenza vaccine is October-November. Persons at high risk for influenza-related complications (e.g., persons aged >65 years and persons aged 6 months-64 years with certain medical conditions), healthcare workers, household members of persons at high risk, and children aged 6 months to <9 years receiving influenza vaccine for the first time are recommended to receive vaccine beginning in October (1) . Because children aged 6-23 months are at increased risk for influenza-related hospitalizations, starting this fall, the Advisory Committee on Immunization Practices is encouraging, when feasible, the vaccination of all children aged 6-23 months and their household contacts and out-of-home caretakers beginning in October (1, 5, 6) . Other healthy persons, including those aged 50-64 years, are recommended to begin receiving vaccine in November. Influenza vaccine should continue to be offered to all unvaccinated persons in December and throughout the influenza season, as long as vaccine supplies are available (1) .
The three manufacturers distributing influenza vaccine in the United States are expected to produce approximately 94 million doses combined, the largest number of trivalent influenza vaccine doses ever projected for a single season. 
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Increase in African Immigrants and Refugees with TuberculosisSeattle-King County, Washington,
1998-2001
The proportion of tuberculosis (TB) cases among foreignborn persons in the United States has increased steadily, accounting for half of reported cases in 2001 for which country-of-origin information was available. During 1998-2001, the annual number of TB cases among African immigrants and refugees in Seattle and all of King County increased approximately threefold to that during 1993-1997. This report summarizes the investigation of cases during 1998-2001 and outlines the public health interventions implemented to prevent TB in this population. The findings indicate that in Seattle-King County, persons at risk for TB who have arrived recently in the United States were primarily from the African-Horn countries of Eritrea, Ethiopia, and Somalia. Primary health-care providers and civil surgeons (i.e., physicians appointed by the Immigration and Naturalization Service to screen for medical conditions as required for changes of immigration status) should be aware of the high TB rate among African immigrants, especially within the first 5 years after immigration, and be alert for severe extrapulmonary forms of TB.
TB surveillance data are derived from case reports submitted to and verified by the Seattle-King County Public Health (SKCPH) TB Control Program. During 1993-1997, fewer than 10 cases of TB in African immigrants were reported each year (5%-10% of the annual total). The number of cases began increasing in 1998 ( Figure) . In 2001, of 139 TB cases reported in Seattle-King County, 28 (20%) were among African immigrants.
During 1998-2001, of Seattle-King County's 486 TB cases, 79 (16%) were among African immigrants, 67 (85%) of whom were from Eritrea, Ethiopia, and Somalia. Two each were from Kenya, Uganda, and Zambia, and one each was from six other African countries (Gambia, Guinea, Liberia, Malawi, Rwanda, and Zaire). Of 281 other foreign-born patients with TB reported during the same period, 68 were from Vietnam, 59 were from the Philippines, 24 were from India, and the remainder were from 69 other countries.
Characteristics of patients and of TB disease were similar for the 67 African-Horn immigrants and the 12 immigrants from other African countries; 40 (51%) cases were among men. Of 69 patients who were tested for human immunodeficiency virus infection, five (7%) tested positive.
The median age of the 79 African immigrants with TB was 27 years (range: 2-70 years); five (6%) patients were aged <15 years, and 62 (78%) were aged <35 years, compared with 117 (40%) of 281 other foreign-born patients aged <35 years with TB reported during the same period (p<0.01). For African immigrants, TB occurred sooner after immigration than for other immigrants. Of 71 cases in African immigrants with known arrival dates, 32 (45%) occurred within 1 year after arrival, and 60 (65%) occurred within 5 years, compared with 38 (16%) and 98 (41%), respectively, of 239 TB cases among other immigrants (p<0.01).
Among African immigrants with TB reported during 1998-2001, a total of 37 (47%) had pulmonary disease, 39 (49%) had extrapulmonary disease, and three (4%) had both, resulting in a total of 42 (53%) patients with extrapulmonary disease. This proportion was greater than the national average of 27% reported in 2000 (1) but similar to the 127 (45%) of 281 immigrants from other continents (p=0.21). Among the 42 African immigrants with extrapulmonary TB, eight (19%) had TB of the spine (i.e., Pott's disease), compared with nine Of the 72 initial isolates of Mycobacterium tuberculosis from African immigrants with TB, four (6%) were resistant to isoniazid but not to rifampin, and one was resistant to isoniazid, rifampin, ethambutol, pyrazinamide, and streptomycin. Of 258 initial isolates from other immigrants, 27 (10%) were resistant to isoniazid but not rifampin, and two were resistant to both isoniazid and rifampin.
In the SKCPH Refugee Screening Program, the number of refugees arriving from Eritrea, Ethiopia, and Somalia into Seattle-King County increased from 59 in 1998 to 425 in 2001. An estimated 10,314 (range: 3,952-16,676) residents of Seattle-King County were born in Africa (2) . On the basis of this denominator, the annual rate of TB for African immigrants was 262 per 100,000 population in 2001. For all of Seattle-King County, the 2001 TB rate was eight.
Medical records for the 27 African immigrants reported with TB in 1998 and 1999 were reviewed for missed opportunities to prevent TB. Among 25 immigrants with complete records, 10 (40%) had received tuberculin skin testing before developing TB. Six of these patients had positive results and started isoniazid treatment for latent TB infection (LTBI); two reportedly completed treatment. Five (20%) other patients had not been tested for LTBI, although they had received primary health-care services before their diagnosis of TB. The remaining 10 (40%) were not known to have received medical care in the United States before their diagnosis of TB. Editorial Note: The findings in this report indicate that in Seattle-King County, the immigrant groups at risk for TB were primarily from the African-Horn countries of Eritrea, Ethiopia, and Somalia. The World Health Organization estimates that the TB rate is 260 per 100,000 population for Ethiopia and 229 for all of Africa (3), rates almost identical to those observed in Seattle-King County. Increases in African immigration and TB are occurring elsewhere; in the United States, the number of refugees from Africa increased from 6,662 in 1998 to an estimated 18,979 in 2001 (4, 5) .
State and local health departments should monitor TB surveillance trends to focus case-finding and prevention activities. Seattle-King County implemented a flexible communitybased approach that establishes partnerships with immigrant service systems, engages groups of immigrants in an exchange of TB information, and employs immigrants to serve as outreach workers in their communities (6) . For example, the SKCPH TB Control Program and the International Medicine Clinic at Harborview Medical Center, Seattle, implemented a pilot program hiring and training recent refugees from three countries (Somalia, the former Soviet Union, and the former Yugoslavia) to work as outreach workers for TB-prevention services targeted to refugees. These workers visit patients who are undergoing treatment for LTBI or TB and serve as mediators between patients and their health-care providers. The workers also assist with other resettlement issues (e.g., social needs, education, and overall health care). Since the program was implemented in 1999, the rate of TB treatment acceptance among targeted refugees increased from 51% (46 of 90) in 1998 to 86% (224 of 260) in 2000, and the rate of treatment completion increased from 50% (23 of 46) to 87% (194 of 224) (6) .
Primary health-care providers and civil surgeons (7, 8) , should be aware of the high TB rate among African immigrants, especially within the first 5 years after immigration, and be alert for severe extrapulmonary forms of TB (e.g., Pott's disease). Immigrants, including refugees, from countries with high rates of TB (3) should be screened for active TB and tested for LTBI when they enter the health-care system. Candidates for treatment of LTBI should be selected and treated in accordance with guidelines from the American Thoracic Society and CDC (9) . 
WNV Surveillance
During the reporting period of September 26-October 2, a total of 409 laboratory-positive human cases of WNVassociated illness were reported from Illinois (n=81), Michigan (n=73), Ohio (n=56), Indiana (n=53), Nebraska (n=32), Louisiana (n=26), Missouri (n=17), Kentucky (n=13), Pennsylvania (n=eight), Iowa (n=seven), Minnesota (n=seven), Mississippi (n=six), Alabama (n=five), New York (n=five), Tennessee (n=five), Wisconsin (n=five), Maryland (n=four), Colorado (n=two), New Jersey (n=two), South Dakota (n=one), and Texas (n=one). During the same period, WNV infections were reported in 684 dead crows and 441 other dead birds. A total of 1,027 veterinary cases were reported (1,026 equine and one other species). During the same period, 521 WNV-positive mosquito pools were reported.
During 2002, a total of 2,530 human cases with laboratory evidence of recent WNV infection have been reported from Illinois (n=599), Michigan (n=343), Ohio (n=288), Louisiana (n=287), Mississippi (n=163), Indiana (n=157), Missouri (n=131), Texas (n=92), Nebraska (n=80), New York (n=51), Kentucky (n=40), Tennessee (n=31), Alabama (n=30), Minnesota (n=26), Pennsylvania (n=26), Iowa (n=25), South Dakota (n=24), Georgia (n=19), Wisconsin (n=19), Virginia (n=16), North Dakota (n=15), Arkansas (n=11), Maryland (n=10), Massachusetts (n=10), Florida (n=eight), Connecticut (n=seven), the District of Columbia (n=six), New Jersey (n=six), Oklahoma (n=four), Colorado (n=three), California (n=one), North Carolina (n=one), and South Carolina (n=one) (Figure) . Among the 2,132 patients for whom data were available, the median age was 56 years (range: 1 month-99 years); 1,150 (54%) were male, and the dates of illness onset ranged from June 10 to September 23. A total of 116 human deaths have been reported. The median age of decedents was 79 years (range: 27-99 years); 70 (60%) deaths were among men. In 
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of blood transfusion and organ transplantation. During August 28-October 2, CDC received reports from 10 states of 15 patients with confirmed West Nile meningoencephalitis (WNME) or meningitis diagnosed after receiving blood components within 1 month of illness onset. CDC has been notified of additional cases among transfusion recipients, but demographic and clinical information is pending. All 15 of these patients resided in areas with high levels of WNV activity. Investigations are ongoing to determine whether transfusion was the source of WNV transmission.
Of the 15 cases, eight (53%) were reported since September 25. One patient, an organ donor from Georgia, was positive for WNV at the time of organ recovery following receipt of multiple blood transfusions (1) . The onset of symptoms for the remaining 14 patients began in July (two patients), August (five patients), and September (seven patients). The reasons for hospitalization included a surgical procedure or obstetric delivery (four patients) and solid organ transplantation (three patients who received an organ from different donors who did not have evidence of WNV infection at the time the organs were recovered). Five patients had hematologic conditions, three patients had myelodysplasia, and two patients had acute myelogenous leukemia. These 15 patients received blood components from a median of 18 donors (range: 2-185 donors). WNME was the probable cause of death for at least three of the four patients who died.
Some of these investigations provide evidence that WNV can be transmitted through blood transfusion. Two patients tested positive for WNV infection after receiving different blood products derived from a single blood donation subsequently found to have evidence of WNV (2) . In another case, WNV was isolated from a unit of frozen plasma that had been withdrawn as a result of the investigation, indicating that the virus can survive in some blood components (1) . In addition to these patients, investigations in Georgia and Florida have demonstrated transmission of WNV in four recipients of solid organs from a single donor (1, 3, 4) .
Patients with WNV infection who have received blood transfusions or organs within the 4 weeks preceding the onset of symptom should be reported to CDC through local public health authorities. Serum or tissue samples should be retained for later studies. In addition, the Public Health Service is expanding an earlier recommendation (1) to request that cases of WNV infection in patients who had onset of symptoms within 2 weeks of blood or organ donation be reported. Prompt reporting of these cases will facilitate withdrawal of potentially infected blood components.
Additional information about WNV activity is available from CDC at http://www.cdc.gov/ncidod/dvbid/westnile/ index.htm and http://www.cindi.usgs.gov/hazard/event/ west_nile/west_nile.html. 
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